Johnny Kao1, Pawel Karwowski1, Jeffrey Pettit1, Austin Kevin Barney1, Christopher Atalla2. 1. Department of Radiation Oncology, Good Samaritan Hospital Medical Center, West Islip, New York, United States. 2. Division of Urology, Good Samaritan Hospital Medical Center, West Islip, New York, United States.
Abstract
OBJECTIVES: The optimal technique to administer image-guided radiation therapy for prostate cancer remains poorly defined. This study assessed outcomes after multiparametric prostate MRI-based planning was delivered with image-guided radiation therapy using prostatic calculi observed on cone beam CT (CBCT). METHODS: Between January 2015 and December 2017, 94 consecutive patients were treated with CBCT-based image-guided radiation therapy (IGRT) without fiducial markers. MRI was routinely incorporated for target delineation and intraprostatic tumor nodules were boosted to allow reduced doses to normal appearing prostate. The primary endpoint was the prevalence of prostatic calcifications while toxicity and biochemical control were secondary endpoints. RESULTS: Median follow-up was 39.7 months with 82% NCCN intermediate to very high risk. Intraprostatic calculi were noted in 68% of patients. The 3-year biochemical control, late grade ≥2 rectal toxicity and late grade ≥2 urinary toxicity rates were 96%, 3 and 7%, respectively. Biochemical control and toxicity were not significantly impacted by the presence of prostatic calculi. CONCLUSION: Prostatic calcifications can serve as natural fiducial markers to allow for non-invasive IGRT for prostate cancer with promising early disease control and toxicity outcomes. ADVANCES IN KNOWLEDGE: Prostate calcification-guided IGRT is technically feasible.
OBJECTIVES: The optimal technique to administer image-guided radiation therapy for prostate cancer remains poorly defined. This study assessed outcomes after multiparametric prostate MRI-based planning was delivered with image-guided radiation therapy using prostatic calculi observed on cone beam CT (CBCT). METHODS: Between January 2015 and December 2017, 94 consecutive patients were treated with CBCT-based image-guided radiation therapy (IGRT) without fiducial markers. MRI was routinely incorporated for target delineation and intraprostatic tumor nodules were boosted to allow reduced doses to normal appearing prostate. The primary endpoint was the prevalence of prostatic calcifications while toxicity and biochemical control were secondary endpoints. RESULTS: Median follow-up was 39.7 months with 82% NCCN intermediate to very high risk. Intraprostatic calculi were noted in 68% of patients. The 3-year biochemical control, late grade ≥2 rectal toxicity and late grade ≥2 urinary toxicity rates were 96%, 3 and 7%, respectively. Biochemical control and toxicity were not significantly impacted by the presence of prostatic calculi. CONCLUSION: Prostatic calcifications can serve as natural fiducial markers to allow for non-invasive IGRT for prostate cancer with promising early disease control and toxicity outcomes. ADVANCES IN KNOWLEDGE: Prostate calcification-guided IGRT is technically feasible.
Authors: Grace G Zeng; Tom S McGowan; Tessa M Larsen; Lisa M Bruce; Natasha K Moran; Jonathan R Tsao; Miller S MacPherson Journal: Int J Radiat Oncol Biol Phys Date: 2008-11-15 Impact factor: 7.038
Authors: Sean S Park; Di Yan; Samuel McGrath; Joshua T Dilworth; Jian Liang; Hong Ye; Daniel J Krauss; Alvaro A Martinez; Larry L Kestin Journal: Int J Radiat Oncol Biol Phys Date: 2011-12-28 Impact factor: 7.038
Authors: Neil Mariados; John Sylvester; Dhiren Shah; Lawrence Karsh; Richard Hudes; David Beyer; Steven Kurtzman; Jeffrey Bogart; R Alex Hsi; Michael Kos; Rodney Ellis; Mark Logsdon; Shawn Zimberg; Kevin Forsythe; Hong Zhang; Edward Soffen; Patrick Francke; Constantine Mantz; Peter Rossi; Theodore DeWeese; Daniel A Hamstra; Walter Bosch; Hiram Gay; Jeff Michalski Journal: Int J Radiat Oncol Biol Phys Date: 2015-04-23 Impact factor: 7.038
Authors: Johnny Kao; Amanda Zucker; Jonathan Timmins; Shankar Taramangalam; Jeffrey Pettit; Aaron J Woodall; Edward Loizides; Andrew T Wong Journal: Mol Clin Oncol Date: 2017-06-08
Authors: Douglas J Moseley; Elizabeth A White; Kirsty L Wiltshire; Tara Rosewall; Michael B Sharpe; Jeffrey H Siewerdsen; Jean-Pierre Bissonnette; Mary Gospodarowicz; Padraig Warde; Charles N Catton; David A Jaffray Journal: Int J Radiat Oncol Biol Phys Date: 2007-03-01 Impact factor: 7.038
Authors: Mariel Cornell; Robert Kaderka; Sebastian J Hild; Xenia J Ray; James D Murphy; Todd F Atwood; Kevin L Moore Journal: Int J Radiat Oncol Biol Phys Date: 2019-10-31 Impact factor: 7.038